Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19

[1]  P. Sivaprakash,et al.  Mucormycosis: An opportunistic pathogen during COVID-19 , 2021, Environmental Research.

[2]  C. D. Dela Cruz,et al.  Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection , 2021, Science Immunology.

[3]  E. Shin,et al.  Type I and III interferon responses in SARS-CoV-2 infection , 2021, Experimental & Molecular Medicine.

[4]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[5]  A. Iwasaki,et al.  The first 12 months of COVID-19: a timeline of immunological insights , 2021, Nature reviews. Immunology.

[6]  J. Schultze,et al.  COVID-19 and the human innate immune system , 2021, Cell.

[7]  Pingping Wang,et al.  COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas , 2021, Cell.

[8]  E. Shin,et al.  SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals , 2021, Immune network.

[9]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[10]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[11]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[12]  I. Amit,et al.  The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing , 2020, medRxiv.

[13]  E. Shin,et al.  The type I interferon response in COVID-19: implications for treatment , 2020, Nature Reviews Immunology.

[14]  Alexander Sczyrba,et al.  Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment , 2020, Cell.

[15]  A. Iwasaki,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.

[16]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[17]  Aaron M. Rosenfeld,et al.  Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.

[18]  S. Perlman,et al.  Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.

[19]  Inkyung Jung,et al.  Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 , 2020, Science Immunology.

[20]  V. Pascual,et al.  Mapping Systemic Lupus Erythematosus heterogeneity at the single-cell level , 2020, Nature Immunology.

[21]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[22]  Aaron J. Wilk,et al.  A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.

[23]  Eric Song,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, bioRxiv.

[24]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[25]  M. Merad,et al.  Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.

[26]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[27]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[28]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[29]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[30]  I. Bruce,et al.  Trial of Anifrolumab in Active Systemic Lupus Erythematosus. , 2019, The New England journal of medicine.

[31]  S. Anderson,et al.  Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and III Interferons. , 2019, Immunity.

[32]  E. Lee,et al.  Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids , 2017, Annals of the rheumatic diseases.

[33]  I. Fraser,et al.  Anti‐Inflammatory Chromatinscape Suggests Alternative Mechanisms of Glucocorticoid Receptor Action , 2017, Immunity.

[34]  Eugenia G. Giannopoulou,et al.  Type I IFNs and TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation , 2017, Nature Immunology.

[35]  G. Stark,et al.  Response to interferons and antibacterial innate immunity in the absence of tyrosine‐phosphorylated STAT1 , 2016, EMBO reports.

[36]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[37]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[38]  D. Park,et al.  Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness , 2015, Proceedings of the National Academy of Sciences.

[39]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[40]  D. Granger,et al.  Blood cells and endothelial barrier function , 2015, Tissue barriers.

[41]  C. Rice,et al.  IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage , 2013, The EMBO journal.

[42]  Gary B. Smith,et al.  The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. , 2013, Resuscitation.

[43]  M. David,et al.  Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.

[44]  B. Lask,et al.  Implications for Treatment , 2011 .

[45]  W. Hörl,et al.  Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. , 2011, Blood.

[46]  Mahboob Rahman,et al.  Glucocorticoid use, other associated factors, and the risk of tuberculosis. , 2006, Arthritis and rheumatism.

[47]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[48]  Sergio Romagnani,et al.  CXC chemokines: the regulatory link between inflammation and angiogenesis. , 2004, Trends in immunology.

[49]  J. Kirwan,et al.  The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. , 1995, The New England journal of medicine.

[50]  M. Schauer,et al.  Binding of hormone accelerates the kinetics of glucocorticoid and progesterone receptor binding to DNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P. Hench,et al.  Adrenocortical Hormone in Arthritis * , 1949, Annals of the rheumatic diseases.

[52]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[53]  E. Cesse,et al.  Lessons from COVID-19 , 2021, Revista Brasileira de Saúde Materno Infantil.

[54]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[55]  M. Ryser-Degiorgis.  Other coronavirus infections , 2012 .